Newsletter | March 5, 2024

03.05.24 -- Does Your Post-Pandemic Planning Include Direct-To-Patient Deliveries?

FEATURED EDITORIAL

Post-Pandemic Planning Now Includes Direct-To-Patient Deliveries

A conversation with Tero Laulajainen, vice president – head of global clinical science and operations, UCB

UCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.

INDUSTRY INSIGHTS

Modern Architecture's Impact On UX In Next-Gen Interactive Response Tech

Article | By Ryan Ridge, YPrime

Explore how interactive response technologies (IRTs) built around microservices models can provide faster initial builds, more rapid change management, and improved built-in test automation.

A Risk-Based Approach To Injectable Combination Product Development

White Paper | By Fran DeGrazio, Diane Paskiet, and Peggy Frandolig, West Pharmaceutical Services, Inc.

Examine how to establish a holistic approach to drug-device combination product (DDCP) development and how to assess and manage risk throughout the development and approval process.

Navigating New EU Trial Regulation Requirements For Clinical Supplies

Article | Catalent

Better understand Clinical Trials Regulation No. 536/201 (CTR) labeling changes and their potential to disrupt traditional clinical supply strategies that adhere to the new requirements.

Sponsor Overcomes Hold And Steers Products Through Development

Case Study | Veristat, Inc.

Uncover how a small biotech company was able to resolve critical regulatory CMC deficiencies to meet FDA requirements.

SOLUTIONS

Supply Chain Logistics Experts Share Best Practices

IQVIA Technologies

Unlock The Power Of Randomization And Trial Supply Management

Medidata, a Dassault Systemes company